PL3368579T3 - Fragmenty przeciwciał ze zmodyfikowanymi regionami zawiasowymi i sposoby ich wytwarzania - Google Patents

Fragmenty przeciwciał ze zmodyfikowanymi regionami zawiasowymi i sposoby ich wytwarzania

Info

Publication number
PL3368579T3
PL3368579T3 PL16795192T PL16795192T PL3368579T3 PL 3368579 T3 PL3368579 T3 PL 3368579T3 PL 16795192 T PL16795192 T PL 16795192T PL 16795192 T PL16795192 T PL 16795192T PL 3368579 T3 PL3368579 T3 PL 3368579T3
Authority
PL
Poland
Prior art keywords
production
methods
antibody fragments
hinge regions
modified hinge
Prior art date
Application number
PL16795192T
Other languages
English (en)
Inventor
Yu-Ju G. Meng
Hok Seon Kim
Ingrid KIM
Christoph Spiess
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL3368579T3 publication Critical patent/PL3368579T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL16795192T 2015-10-30 2016-10-27 Fragmenty przeciwciał ze zmodyfikowanymi regionami zawiasowymi i sposoby ich wytwarzania PL3368579T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562248792P 2015-10-30 2015-10-30
US201662346905P 2016-06-07 2016-06-07
PCT/US2016/059137 WO2017075229A1 (en) 2015-10-30 2016-10-27 Hinge modified antibody fragments and methods of making
EP16795192.0A EP3368579B1 (en) 2015-10-30 2016-10-27 Hinge modified antibody fragments and methods of making

Publications (1)

Publication Number Publication Date
PL3368579T3 true PL3368579T3 (pl) 2022-03-21

Family

ID=57288500

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16795192T PL3368579T3 (pl) 2015-10-30 2016-10-27 Fragmenty przeciwciał ze zmodyfikowanymi regionami zawiasowymi i sposoby ich wytwarzania

Country Status (9)

Country Link
US (2) US10662254B2 (pl)
EP (2) EP4036120A1 (pl)
JP (4) JP6920292B2 (pl)
CN (2) CN109071674B (pl)
ES (1) ES2904553T3 (pl)
HR (1) HRP20220064T1 (pl)
PL (1) PL3368579T3 (pl)
SI (1) SI3368579T1 (pl)
WO (1) WO2017075229A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4036120A1 (en) * 2015-10-30 2022-08-03 F. Hoffmann-La Roche AG Hinge modified antibody fragments and methods of making
US11254734B2 (en) * 2016-11-14 2022-02-22 Morphosys Ag Fab molecules with a rodent hinge region and a non-rodent CH1 region
CA3172530A1 (en) 2021-02-25 2022-09-01 Spencer PARK Ror1 targeting chimeric antigen receptor
CN116981695A (zh) * 2022-05-06 2023-10-31 上海药明合联生物技术有限公司 含工程化铰链区的抗体及其应用
CN115873833B (zh) * 2022-11-08 2024-08-16 上海泰昶生物技术有限公司 生产免疫球蛋白g降解酶的工程菌株和工艺
CN119505008A (zh) * 2023-08-23 2025-02-25 菲鹏生物股份有限公司 免疫球蛋白及其多聚体

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
DE60022369T2 (de) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
EP1242438B1 (en) 1999-12-29 2006-11-08 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
JP4753578B2 (ja) * 2002-06-03 2011-08-24 ジェネンテック， インコーポレイテッド 合成抗体ファージライブラリー
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
SE0203226D0 (sv) * 2002-10-31 2002-10-31 Amersham Biosciences Ab Immunoglobulin bindning site
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
CN107213469A (zh) 2003-11-06 2017-09-29 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
US7276585B2 (en) * 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
AU2005267720B2 (en) * 2004-08-05 2012-02-23 Genentech, Inc. Humanized anti-cmet antagonists
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2006166905A (ja) * 2004-11-17 2006-06-29 Oita Univ 狂犬病ウイルスを効果的に中和するヒトＦａｂ抗体遺伝子群
WO2009011941A2 (en) * 2007-04-04 2009-01-22 The Government Of U.S.A., As Represented By The Secretary, Departmetnt Of Health & Human Services Monoclonal antibodies against dengue and other viruses with deletion in fc region
KR20080111347A (ko) * 2007-06-18 2008-12-23 이수앱지스 주식회사 암 특이적 마커에 결합하는 재조합 항체 및 그의 용도
CR20170001A (es) * 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
EP2358390A1 (en) * 2008-11-13 2011-08-24 Emergent Product Development Seattle, LLC Cd37 immunotherapeutic combination therapies and uses thereof
WO2010122148A1 (en) * 2009-04-24 2010-10-28 Boehringer Ingelheim International Gmbh An improved antibody domain and antibody fragments and antibodies based thereon
GB0920127D0 (en) * 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
WO2012009704A2 (en) * 2010-07-16 2012-01-19 Avantgen, Inc. Novel peptides and uses thereof
PH12014500380A1 (en) * 2011-08-17 2022-05-02 Glaxo Group Ltd Modified proteins and peptides
AR087601A1 (es) * 2011-08-23 2014-04-03 Roche Glycart Ag Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de utilizacion
MX2015011712A (es) * 2013-03-06 2016-04-04 Merrimack Pharmaceuticals Inc Anticerpos biespecificos fc en fila anti-c-met.
BR112015021595A2 (pt) * 2013-03-11 2017-10-10 Genzyme Corp anticorpos anti-tgf-beta engenheirados e fragmentos de ligação do antígeno
SG11201606983SA (en) * 2014-02-27 2016-09-29 Allergan Inc COMPLEMENT FACTOR Bb ANTIBODIES
EP4036120A1 (en) * 2015-10-30 2022-08-03 F. Hoffmann-La Roche AG Hinge modified antibody fragments and methods of making
NZ741780A (en) * 2015-10-30 2019-11-29 Genentech Inc Anti-htra1 antibodies and methods of use thereof

Also Published As

Publication number Publication date
JP7413322B2 (ja) 2024-01-15
EP3368579A1 (en) 2018-09-05
ES2904553T3 (es) 2022-04-05
CN109071674A (zh) 2018-12-21
JP6920292B2 (ja) 2021-08-18
HRP20220064T1 (hr) 2022-04-15
US20200308304A1 (en) 2020-10-01
SI3368579T1 (sl) 2022-04-29
JP2019504820A (ja) 2019-02-21
US10662254B2 (en) 2020-05-26
JP2026035577A (ja) 2026-03-04
JP2024045138A (ja) 2024-04-02
JP2021181452A (ja) 2021-11-25
CN109071674B (zh) 2022-08-05
US20180305462A1 (en) 2018-10-25
CN115925962A (zh) 2023-04-07
EP4036120A1 (en) 2022-08-03
WO2017075229A1 (en) 2017-05-04
EP3368579B1 (en) 2021-11-24

Similar Documents

Publication Publication Date Title
IL290972A (en) Anti-vista antibodies and fragments
IL288391A (en) Anti-cd123 antibodies and conjugates and derivatives thereof
IL259643A (en) Antibodies and antibody fragments for site-specific conjugation
PL3258951T3 (pl) Przeciwciała anty-pvrig i sposoby ich zastosowania
IL250566B2 (en) Anti-lag3 antibodies and antigen-binding fragments
PL3280441T3 (pl) Przeciwciała przeciwko sortilinie i sposoby ich stosowania
DK3313882T3 (da) Anti-VISTA antistoffer og fragmenter
PL3148579T3 (pl) Przeciwciała anty-gitr i sposoby ich zastosowania
IL251045B (en) Macropinocytosing human anti-cd46 antibodies and targeted cancer therapeutics
EP3551220C0 (en) ANTI-TAU ANTIBODIES AND ITS USES
HUE050750T2 (hu) CTLA-4 elleni antitestek és eljárások alkalmazásukra
PL4234581T3 (pl) Przeciwciała terapeutyczne i ich zastosowania
PL3380522T3 (pl) Cząsteczki przeciwciał wobec april i ich zastosowania
DK3316909T3 (da) Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder
HUE045216T2 (hu) Anti-CD79B antitestek és alkalmazási eljárások
DK3149042T3 (da) PD-L1-antistoffer og anvendelser deraf
DK3368655T3 (da) Forbedret proteinekspression og fremgangsmåder dertil
PL3319612T3 (pl) Oksysterole i sposoby ich stosowania
PL3368579T3 (pl) Fragmenty przeciwciał ze zmodyfikowanymi regionami zawiasowymi i sposoby ich wytwarzania
PL3455261T3 (pl) Przeciwciała anty-ror2, fragmenty przeciwciał, ich immunokoniugaty oraz ich zastosowania
EP3878861C0 (en) MUTATED CL AND/OR CH1 ANTIBODIES FOR DRUG CONJUGATION
DK3380496T3 (da) Forbedret proteinproduktion og fremgangsmåder hertil
HUE052993T2 (hu) Fejlesztett újrahajtogatási eljárás antitest fragmensekhez
PL3309149T3 (pl) Kryształ 6-bromo-3-hydroksy-2-pirazynokarboksamidu i sposób jego wytwarzania
DK3253694T3 (da) Transportbåndsmodul med trindelt hængselspassage